Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans

Anne Nissen; Mikkel Christensen; Filip K Knop; Tina Vilsbøll; Jens Juul Holst; Bolette Hartmann

doi:10.1210/jc.2014-2547

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans

Anne Nissen, Mikkel Christensen, Filip K Knop, Tina Vilsbøll, Jens Juul Holst, Bolette Hartmann

74 Citationer (Scopus)

Abstract

BACKGROUND: In humans, the pronounced postprandial reduction in bone resorption (decreasing bone resorption markers by around 50%) has been suggested to be caused by gut hormones. Glucose-dependent insulinotropic polypeptide (GIP) is a peptide hormone secreted postprandially from the small intestine. The hormone is known as an incretin hormone, but preclinical studies have suggested that it may also influence bone metabolism, showing both antiresorptive and anabolic effects as reflected by changes in biomechanical measures, microarchitecture, and activity of the bone cells in response to GIP stimulation. Its role in human bone homeostasis, however, is unknown.

OBJECTIVE: To examine the effect of GIP administration on bone resorption in humans.

MATERIALS AND METHODS: Plasma samples were obtained from 10 healthy subjects during four conditions: euglycemic (5 mmol/L) and hyperglycemic (12 mmol/L) 90-minute glucose clamps with co-infusion of GIP (4 pmol/kg/min for 15 min, followed by 2 pmol/kg/min for 45 min) or placebo. The samples were analyzed for concentrations of degradation products of C-terminal telopeptide of type I collagen (CTX), a bone resorption marker. RESULTS regarding effects on pancreatic hormone secretion have been published.

RESULTS: During euglycemia, the decremental area under the curve in CTX was significantly (P < .001) higher during GIP infusion (2084 ± 686 % × min) compared to saline infusion (656 ± 295 % × min). During hyperglycemia, GIP infusion significantly (P < .001) augmented the decremental area under the curve to 2785 ± 446 % × minutes, compared to 1308 ± 448 % × minutes during saline infusion, with CTX values corresponding to 49% of basal values.

CONCLUSIONS: We conclude that GIP reduces bone resorption in humans, interacting with a possible effect of hyperglycemia.

Originalsprog	Engelsk
Tidsskrift	The Journal of clinical endocrinology and metabolism
Vol/bind	99
Udgave nummer	11
Sider (fra-til)	E2325-9
Antal sider	5
ISSN	0021-972X
DOI	https://doi.org/10.1210/jc.2014-2547
Status	Udgivet - 1 nov. 2014

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1210/jc.2014-2547

Citationsformater

@article{47e27e0152544db191a220a1267f16c5,

title = "Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans",

abstract = "BACKGROUND: In humans, the pronounced postprandial reduction in bone resorption (decreasing bone resorption markers by around 50%) has been suggested to be caused by gut hormones. Glucose-dependent insulinotropic polypeptide (GIP) is a peptide hormone secreted postprandially from the small intestine. The hormone is known as an incretin hormone, but preclinical studies have suggested that it may also influence bone metabolism, showing both antiresorptive and anabolic effects as reflected by changes in biomechanical measures, microarchitecture, and activity of the bone cells in response to GIP stimulation. Its role in human bone homeostasis, however, is unknown.OBJECTIVE: To examine the effect of GIP administration on bone resorption in humans.MATERIALS AND METHODS: Plasma samples were obtained from 10 healthy subjects during four conditions: euglycemic (5 mmol/L) and hyperglycemic (12 mmol/L) 90-minute glucose clamps with co-infusion of GIP (4 pmol/kg/min for 15 min, followed by 2 pmol/kg/min for 45 min) or placebo. The samples were analyzed for concentrations of degradation products of C-terminal telopeptide of type I collagen (CTX), a bone resorption marker. RESULTS regarding effects on pancreatic hormone secretion have been published.RESULTS: During euglycemia, the decremental area under the curve in CTX was significantly (P < .001) higher during GIP infusion (2084 ± 686 % × min) compared to saline infusion (656 ± 295 % × min). During hyperglycemia, GIP infusion significantly (P < .001) augmented the decremental area under the curve to 2785 ± 446 % × minutes, compared to 1308 ± 448 % × minutes during saline infusion, with CTX values corresponding to 49% of basal values.CONCLUSIONS: We conclude that GIP reduces bone resorption in humans, interacting with a possible effect of hyperglycemia.",

keywords = "Adult, Biological Markers, Blood Glucose, Bone Resorption, Bone and Bones, Collagen Type I, Fasting, Gastric Inhibitory Polypeptide, Glucose Clamp Technique, Humans, Hyperglycemia, Male, Peptides, Young Adult",

author = "Anne Nissen and Mikkel Christensen and Knop, {Filip K} and Tina Vilsb{\o}ll and Holst, {Jens Juul} and Bolette Hartmann",

year = "2014",

month = nov,

day = "1",

doi = "10.1210/jc.2014-2547",

language = "English",

volume = "99",

pages = "E2325--9",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans

AU - Nissen, Anne

AU - Christensen, Mikkel

AU - Knop, Filip K

AU - Vilsbøll, Tina

AU - Holst, Jens Juul

AU - Hartmann, Bolette

PY - 2014/11/1

Y1 - 2014/11/1

N2 - BACKGROUND: In humans, the pronounced postprandial reduction in bone resorption (decreasing bone resorption markers by around 50%) has been suggested to be caused by gut hormones. Glucose-dependent insulinotropic polypeptide (GIP) is a peptide hormone secreted postprandially from the small intestine. The hormone is known as an incretin hormone, but preclinical studies have suggested that it may also influence bone metabolism, showing both antiresorptive and anabolic effects as reflected by changes in biomechanical measures, microarchitecture, and activity of the bone cells in response to GIP stimulation. Its role in human bone homeostasis, however, is unknown.OBJECTIVE: To examine the effect of GIP administration on bone resorption in humans.MATERIALS AND METHODS: Plasma samples were obtained from 10 healthy subjects during four conditions: euglycemic (5 mmol/L) and hyperglycemic (12 mmol/L) 90-minute glucose clamps with co-infusion of GIP (4 pmol/kg/min for 15 min, followed by 2 pmol/kg/min for 45 min) or placebo. The samples were analyzed for concentrations of degradation products of C-terminal telopeptide of type I collagen (CTX), a bone resorption marker. RESULTS regarding effects on pancreatic hormone secretion have been published.RESULTS: During euglycemia, the decremental area under the curve in CTX was significantly (P < .001) higher during GIP infusion (2084 ± 686 % × min) compared to saline infusion (656 ± 295 % × min). During hyperglycemia, GIP infusion significantly (P < .001) augmented the decremental area under the curve to 2785 ± 446 % × minutes, compared to 1308 ± 448 % × minutes during saline infusion, with CTX values corresponding to 49% of basal values.CONCLUSIONS: We conclude that GIP reduces bone resorption in humans, interacting with a possible effect of hyperglycemia.

AB - BACKGROUND: In humans, the pronounced postprandial reduction in bone resorption (decreasing bone resorption markers by around 50%) has been suggested to be caused by gut hormones. Glucose-dependent insulinotropic polypeptide (GIP) is a peptide hormone secreted postprandially from the small intestine. The hormone is known as an incretin hormone, but preclinical studies have suggested that it may also influence bone metabolism, showing both antiresorptive and anabolic effects as reflected by changes in biomechanical measures, microarchitecture, and activity of the bone cells in response to GIP stimulation. Its role in human bone homeostasis, however, is unknown.OBJECTIVE: To examine the effect of GIP administration on bone resorption in humans.MATERIALS AND METHODS: Plasma samples were obtained from 10 healthy subjects during four conditions: euglycemic (5 mmol/L) and hyperglycemic (12 mmol/L) 90-minute glucose clamps with co-infusion of GIP (4 pmol/kg/min for 15 min, followed by 2 pmol/kg/min for 45 min) or placebo. The samples were analyzed for concentrations of degradation products of C-terminal telopeptide of type I collagen (CTX), a bone resorption marker. RESULTS regarding effects on pancreatic hormone secretion have been published.RESULTS: During euglycemia, the decremental area under the curve in CTX was significantly (P < .001) higher during GIP infusion (2084 ± 686 % × min) compared to saline infusion (656 ± 295 % × min). During hyperglycemia, GIP infusion significantly (P < .001) augmented the decremental area under the curve to 2785 ± 446 % × minutes, compared to 1308 ± 448 % × minutes during saline infusion, with CTX values corresponding to 49% of basal values.CONCLUSIONS: We conclude that GIP reduces bone resorption in humans, interacting with a possible effect of hyperglycemia.

KW - Adult

KW - Biological Markers

KW - Blood Glucose

KW - Bone Resorption

KW - Bone and Bones

KW - Collagen Type I

KW - Fasting

KW - Gastric Inhibitory Polypeptide

KW - Glucose Clamp Technique

KW - Humans

KW - Hyperglycemia

KW - Male

KW - Peptides

KW - Young Adult

U2 - 10.1210/jc.2014-2547

DO - 10.1210/jc.2014-2547

M3 - Journal article

C2 - 25144635

SN - 0021-972X

VL - 99

SP - E2325-9

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

IS - 11

ER -

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater